Efficacy and safety of baricitinib in the treatment of moderate-to-severe atopic dermatitis: a clinical observation
Liu Bo, Song Xiaoting, Liao Shuanglu, Yu Miao, Luan Tingting, Li Ruoyu, Zhao Zuotao
Department of Dermatology and Venereology, Peking University First Hospital, Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, National Clinical Research Center for Skin and Immune Diseases, Beijing 100034, China
Liu Bo, Song Xiaoting, Liao Shuanglu, Yu Miao, Luan Tingting, Li Ruoyu, Zhao Zuotao. Efficacy and safety of baricitinib in the treatment of moderate-to-severe atopic dermatitis: a clinical observation[J]. Chinese Journal of Dermatology, 2022, 55(4): 304-307.doi:10.35541/cjd.20210474
Wollenberg A, Barbarot S, Bieber T, et al. Consensus⁃based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I[J]. J Eur Acad Dermatol Venereol, 2018,32(5):657⁃682. doi: 10.1111/jdv.14891.
[2]
Moura RA, Fonseca JE. JAK inhibitors and modulation of B cell immune responses in rheumatoid arthritis[J]. Front Med (Lausanne), 2020,7:607725. doi: 10.3389/fmed.2020.607725.
[3]
Guan Q, Ma Y, Aboud L, et al. Targeting IL⁃23 by employing a p40 peptide⁃based vaccine ameliorates murine allergic skin and airway inflammation[J]. Clin Exp Allergy, 2012,42(9):1397⁃1405. doi: 10.1111/j.1365⁃2222.2012.04022.x.
[4]
Pan Y, Xu L, Qiao J, et al. A systematic review of ustekinumab in the treatment of atopic dermatitis[J]. J Dermatolog Treat, 2018,29(6):539⁃541. doi: 10.1080/09546634.2017.1406894.
[5]
Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis[J]. J Clin Cell Immunol, 2011,2(3):110. doi: 10.4172/2155⁃9899. 1000110.
[6]
Cartron AM, Nguyen TH, Roh YS, et al. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality[J]. Clin Exp Dermatol, 2021,46(5):820⁃824. doi: 10.1111/ced.14567.
Radi G, Simonetti O, Rizzetto G, et al. Baricitinib: the first Jak inhibitor approved in Europe for the treatment of moderate to severe atopic dermatitis in adult patients[J]. Healthcare (Basel), 2021, 9(11):1575. doi: 10.3390/healthcare9111575.
[9]
Urits I, Israel J, Hakobyan H, et al. Baricitinib for the treatment of rheumatoid arthritis[J]. Reumatologia, 2020,58(6):407⁃415. doi: 10.5114/reum.2020.102006.